EGFR and non-small cell lung carcinoma: Multiple randomized controlled studies have shown that first-generation selective EGFR-TKI represented by gefitinib can significantly improve the progression-free survival time of patients with advanced EGFR-mutation-positive non-small cell lung cancer compared with chemotherapy, and the adverse reactions of grade 3 and above are significantly lower than those of chemotherapy.